GSK reports Jemperli rectal cancer trial results
GSK (NYSE:GSK) reported positive interim results from the Phase II AZUR-1 trial of Jemperli (dostarlimab) in patients with stage II/III mismatch repair deficient or microsatellite instability-high locally advanced rectal cancer, with the study meeting its primary objective.










